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ABSTRACT 
Introduction: The purpose of this study was to evaluate the relationship between 
adherence to antidepressants (AD) and all-cause mortality in a population-based cohort of 
patients with Parkinson’s Disease (PD). 
 
Methods: From a database of more than 4 million people, 8,553 patients with PD who 
purchased an AD at least once between the years 2008-2011 were retrospectively 
followed for all-cause mortality over 4-years. Adherence was measured as a ratio 
between dispensed and prescribed durations and was modeled as: non-adherence (<20%, 
n=1,566), poor (20%-50%, n=1,184), moderate (50% - 80%, n=1,584), and good (>80%, 
n=4,219) adherence. Multivariable survival analyses adjusted for demographic and 
clinical variables including physical comorbidities known to influence mortality were 
conducted, however there was no adjustment for other psychiatric disorders and 
medications. 
 
Results: Unadjusted mortality rates were 20.4%, 25.1%, 23.4% and 25.6% in those 
classified as non-adherent, poor, moderate and good adherence respectively (χ2=18.45, 
p<0.0001). The non-adherent and poor adherence groups had significantly increased 
adjusted mortality hazard ratios (HR) of 1.43 (CI: 1.26-1.62) and 1.26 (CI: 1.1-1.44) 
respectively compared to the good adherence group. Using the same model, the adjusted 
HR for death among males was 1.49 [95% CI: 1.36 – 1.62] compared to females.  People 
with PD and Charslon's Comorbidity Index score of 3-4 (HR 1.3, P<0.001) and 5+ (HR 
1.78, P<0.001) were more likely to die than those with 0-2 comorbidities.   
 
Conclusions: Our findings suggest that poor adherence to AD is associated with 
increased all-cause mortality in people with PD. Given the high prevalence of depression 
and AD effectiveness, efforts to promote adherence should be prioritized in clinical 
practice.   
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1. INTRODUCTION 
Parkinson's disease (PD) is a progressive neurodegenerative disorder, which is 
associated with considerable reductions in quality of life, morbidity and mortality [1]. 
Traditionally, PD was defined according to its motor manifestations: tremor, 
bradykinesia, rigidity and postural instability. It is now considered as a complex 
condition with additional non-motor symptoms (NMS), such as olfactory dysfunction, 
pain, sleep behavior disturbances, gastrointestinal symptoms, skin abnormalities and 
psychiatric disorders [2]. The PRIAMO study [3] found that neuropsychiatric features 
were the most frequent (67%) NMS, and included, among other, depression, anxiety, 
hallucinations, apathy, and aggressive behavior.  
Depression is considered the most prevalent psychiatric symptom in PD [4,5]. 
The presence of depressive symptoms is associated with decreased quality of life and less 
favorable motor outcomes [6,7,8]. It is estimated that up to 50% of patients diagnosed 
with PD also have depressive symptoms [4,6], and between 10-20% have major 
depressive disorder (MDD) [9]. Whilst the underlying mechanisms for depression in PD 
are not fully elucidated, alterations in brain structure, neurotransmitters, and 
inflammatory and neurotrophic factors all play a role [10].  Moreover, psychosocial 
factors, higher levels of pain and deterioration in mobility impact on mental health in 
people with PD [10]. 
A frontline approach to tackling depression and in particular MDD is 
Antidepressants (AD) medication.  AD are an effective treatment for MDD and within 
the context of other physical comorbidities [11], including patients with neurologic 
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disorders [12].  More recently, there is a growing evidence base for AD use in people 
with PD [12,13].   
Ultimately, AD treatment outcomes are highly influenced by adherence rates [14].  
In MDD, low adherence to AD medication has been identified as a risk factor for 
emergency department visits, hospitalization rates and an increased severity of depression 
[15].  Medication adherence is known to be variable and low in people with PD and is 
associated with worse health outcomes and increased financial costs [16].  
Surprisingly, the influence of AD adherence on outcomes in people with PD is 
relatively unknown.  In particular, the relationship between antidepressant adherence and 
mortality is not established.  To our knowledge, only one study has investigated AD use 
and mortality in people with PD [17]. The authors established that people with PD taking 
selective serotonin reuptake inhibitors (SSRI) and/ or serotonin-noradrenaline re-uptake 
inhibitors (SNRI) AD were more likely to die than a) people with PD not taking AD 
medication (Odds ratio (OR) 1.19, p=0.01) and b) age and sex matched controls (OR 
1.77, p<0.01).  Whilst this study advanced the field, a number of key limitations persist.  
First, the authors did not differentiate between rates of AD adherence among their 
sample.  Second, the authors did not consider the impact of pertinent confounders, known 
to influence mortality, such as the presence of physical comorbidities. Moreover, 
although they adjust for socioeconomic factors in the selection of patients and controls, 
they did not adjust for socioeconomic factors in the comparison of survival within PD. 
Given the aforementioned gaps and limitations within the literature, our primary 
objective was to evaluate the association between all-cause mortality rates and adherence 
to AD among a representative cohort of people with PD from a database covering more 
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than 4 million individuals, taking into account important confounders. We hypothesized 
that lower levels of adherence to antidepressants, would increase an individual's with PD 
risk of mortality in an inverse dose response manner.    
2. METHODS 
2.1 Population and study period 
Data from the integrated medical records of Clalit Health Services (CHS), the 
largest health provider in Israel, covering over 4 million subjects (53% of the nation 
population) was utilized in the current study.   The CHS database is described in full in 
our previous publication [18]. In summary, the database includes demographic 
information, diagnoses from ambulatory services, family physicians, hospital admissions 
and specialists, drug prescriptions, laboratory tests and imaging results.  
We retrospectively analyzed the entire CHS patient population during the study period 
(1.1.2008 until 1.1.2012) across all ages (N=4,056,700). We included all patients with at 
least one prescription for an AD during the study period and a clinical diagnosis of 
Parkinson's Disease (PD) ICD code G.20 (N=9,884). All Food and Drug Administration 
(FDA) approved AD were included for the current paper. Extraction was based on the 
WHO Anatomical Therapeutic Chemical (ATC) code N06A. In the final analyses we 
included only AD users, specifically patients with PD who purchased at least one 
prescription (N=8,553). Access to the data warehouse and the analyses were approved for 
this study by the lalit Health Services Institutional Review Board. 
 
2.2 Measures 
2.2.1 Primary Outcome 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Shoval et al: Adherence to antidepressants in Parkinson patients and mortality  
6 
 
A record of death from any cause during the four-year study period (produced by the 
Ministry for Interior Affairs) was the primary study outcome. Patients were followed-up 
from entry to the study (i.e. prescription of AD) until death or were censored at the end of 
the study period. 
 
2.3 Main predictor 
2.3.1 Adherence to antidepressants  
The adherence to antidepressants measure was modeled on the basis of the concept of 
medication possession ratio (data comes from CHS pharmacies dispensing) with the 
addition of physician prescription data (derived from the electronic record), as previously 
described in detail [19].  
Study participation duration was calculated as the continuous period between the first and 
the last prescribed AD. Adherence was defined as the period of AD purchased 
prescriptions (months), during follow-up, divided by study participation duration 
(months). Thus it reflects adherence over the period for which AD were known to be 
prescribed. Adherence was calculated across all AD groups used. Switching between 
different AD compounds was not taken into account. 
ℎ		% =
Duration	of		AD	prescriptions		Months
Duration	of	continous	&'	AD		Months
(	100 
 
Adherence is reported as a percentage score for each patient. Patients with adherence 
below 20% were considered non-adherent, those with 20%-50% adherence were 
considered poorly adherent, those with 50%-80% were considered to have a moderate 
adherence and patients with adherence above 80% were considered to have good 
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adherence.  The adherence categorization was based on previously published data 
utilizing this database [20].   
2.4 Covariates  
We collected the following socio-demographic and clinical variables at study entry: age 
(categorized into 0-18, 18-24, 24-40, 40-64, 65-74, 75-84, 85+ years), gender and 
socioeconomic status (based on ecological data). We extracted all available data on 
physical comorbidities diagnosed by a physician (ICD-10 diagnoses). Based on these 
data, we calculated the Charlson's Comorbidity Index (CCI), the most widely used 
clinical index for the evaluation of comorbidities. The CCI  weighs twenty chronic 
conditions as predictors of 1-year relative risk of death, and scores between 1 to 20 [21]. 
 
2.5 Analysis 
Statistical analysis was conducted using SPSS version 20 (IBM Corporation, Armonk, 
New York). We performed descriptive statistics of socio-demographics, co-morbidities, 
and adherence levels across the total study population as well as across the four 
adherence level groups. Univariate analyses were used to assess the association between 
socio-demographics and clinical covariates and those who died or survived during the 
study period. The multivariable Cox proportional hazard regression model was used to 
assess the adjusted association between risk of death and adherence level of AD 
medication controlling for the confounders found to be significant in the univariate 
analysis (age, gender and physical co-morbidities modeled as CCI).We tested the 
assumptions of the proportional hazard model using log (-log) plots. Hazard ratios (HR) 
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and their 95% confidence interval (95%CI) are reported. P<0.05 was considered 
significant. All analyses were two-tailed. 
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3. RESULTS 
3.1 Population Characteristics 
Population characteristics and mortality rates distributed among variables are shown in 
Table 1. Briefly, among the 8,553 individuals in the study, almost 80% of the study 
population was above 65 years old. The most prevalent co-morbidities among the study 
population were: hypertension (69.8%), diabetes mellitus (32.9%), ischemic heart disease 
(36.2%) and past stroke (23.3%). The most frequent concomitant drugs used were: statins 
(65.8%), acetyl-salicylic acid (58.7%), anxiolytics (52.4%), non-steroidal anti-
inflammatory drugs (49.7%), anticonvulsants (34.3%) and antipsychotics (29.6%). 
Males had a significantly higher unadjusted mortality rate versus females (27.9% vs.21%, 
respectively, χ2=56.38, p<0.0001). There was no significant difference in mortality 
according to socioeconomic status.  People with higher CCI scores were more likely to 
die (39.8% on CCI >5 vs. 17.8% on CCI 0-2, p<0.0001). 
The mean follow-up time of the study period was 27.6±15.6 months (range 1–47 months, 
median 30 months). The mean follow-up time of survivors was 30.7±15.2 months and the 
mean time to death among those who died was 17.5±12 months. 
 
3.2 Adherence 
Only 9.9% of the study sample discontinued their AD within a month after prescription 
(i.e. only made a single purchase) and 28.4% of the study sample discontinued the AD 
within 6 months. The adherence distribution indicated that 18.4% of AD users were non-
adherent (n=1,566), 13.8% had poor adherence (n=1,184), 18.5% had moderate 
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adherence (n=1,584) and almost half (49.3%) had good adherence (n=4,219).  Unadjusted 
Mortality rates were: 20.4%, 25.1%, 23,4% and 25.6% in those classified as non-
adherent, poor, moderate and good adherence respectively (χ2=18.45, p<0.0001). 
 
3.3 Multivariable analysis 
The Cox proportional hazards model included mortality as the main outcome and 
variables significantly associated with mortality in the univariate analyses as covariates. 
Adjusted associations between adherence to AD and mortality appear in Table 2.  
Using the same model, the adjusted HR for death among males was 1.49 [95% CI: 1.36 – 
1.62] compared to females. Patients with CCI score of 3-4 (HR 1.3 [95% CI: 1.17 – 
1.44], p<0.001) and 5+ (HR 1.78, [95% CI: 1.6 – 1.98], p<0.001) were at increased risk 
of all-cause mortality versus those scoring 0-2.  Further adjustment to the use of 
antipsychotic compound at study entry resulted in HR for mortality 1.35 [95% CI: 1.18 – 
1.54] for >80% adherence and HR 1.28 [95% CI: 1.12 – 1.45] for 50%-80% adherence. 
 
4. DISCUSSION 
The current study found that people who were non-adherent (n=1,566) or had 
poor adherence (n=1,184) with AD were at elevated risk of mortality by 43% and 26%, 
respectively, compared to people with PD and good adherence to AD medication 
(n=4,219).  To our knowledge, the current study is the largest to investigate the 
relationship between antidepressant medication adherence and mortality in people with 
PD.  Moreover, our study is the first to demonstrate the inverse relationship between 
adherence to these compounds and increased mortality risk, which was only evident after 
important confounders were considered.   
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Only one study has previously investigated the impact of AD medication and 
mortality [17] in PD patients.  That study included 510 adults with PD taking SSRI/ 
SNRI medication and established that antidepressant use (classified as a binary variable), 
was associated with an increased risk of mortality (HR 1.19, p=0.01).  Whilst helpful, the 
relatively small sample size, the reliance of AD adherence based upon a binary 
classification and the fact the authors only adjusted for few confounders (age, sex and 
medication cessation) are important limitations. Our previous studies have suggested that 
there is an inverse association between adherence and mortality risk [18,22], a 
relationship which has been noted in other populations [22].  The unadjusted mortality 
rates in the current study suggested a linear increased risk in tandem with AD adherence, 
which at first glance appears to support the previous study by Fransden et al (2016) [17].  
However, the strength of our dataset is that we were able to accurately collate 
information on additional important confounders such as socioeconomic status and 
physical comorbidities defined according to ICD 10 criteria.  Previous research in people 
with MDD has demonstrated that the relationship between depression and mortality is 
strongly influenced by the type and number of comorbidities [23]. Within our data set, 
the univariate analysis demonstrated an incremental increased risk in mortality in people 
with PD who have more physical comorbidities.  This suggests that physical 
comorbidities play an important role in the increased risk of mortality in those with PD 
and a factor that we adjusted for in the final model.   Within our dataset we found that 
hypertension (69.8%), diabetes mellitus (32.9%), ischemic heart disease (36.2%) and past 
stroke (23.3%) were highly prevalent in our representative cohort of people with PD.  
Cardiovascular diseases are known to be leading causes of premature mortality in the 
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general population [24] therefore these results are somewhat expected.  Whilst future 
studies should seek to clarify the precise role of the physical comorbidities and 
antidepressant adherence on mortality in people with PD, the results from our study 
demonstrate it is essential that important confounders are considered when attempting to 
disentangle the relationship between antidepressant medication and mortality in PD.  In 
addition, increasing age was a factor that once adjusted for in the multivariate model was 
associated with an increased HR for premature mortality among those with lower AD 
adherence.  Again, this is hardly surprising, since this is a relationship commonly 
observed in the general population.   
Given that anxiety and depression are leading contributors to reduced quality of 
life in people with PD [25] and that antidepressants appear effective in improving 
depressive symptoms, our data suggest the clinical imperative of encouraging people with 
PD to be adherent to antidepressant medication.  In particular, people who were most 
adherent to AD medication appear to have the least risk of premature mortality.  A recent 
randomized control trial [26] demonstrated that adherence therapy resulted in improved 
medication adherence, quality of life, mobility, activities of daily living, emotional 
wellbeing, cognition, communication, and body discomfort. 
In the current study, the mortality HR in PD patients who were non-adherent 
compared to good adherence was increased by 40%. Interestingly, this magnitude is 
much higher than the AD effect we previously demonstrated in using similar 
methodology. In the general population mortality risk increased by 15% [18] while in 
patients with Ischemic Heart disease it was increased by 13% [22,27]. A possible 
explanation might be that AD adherence in this specific population might have 
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synergistic effect on disease course, combined with anti-parkinsonian drugs.  However, at 
this stage, this is based simply on a hypothesis and clearly more research is required to 
better elucidate such mechanisms.  Such research in the first instance may wish to 
confirm/ refute our findings regarding adherence and mortality in people with PD. 
The exact reasons why non adherence to antidepressant medication is associated 
with increased mortality is not yet fully elucidated. The association between adherence to 
AD and survival in PD patients may have several putative mechanisms. Adherence to AD 
is presumed to reduce depression and anxiety burden and may thus promote adherence to 
other medications [28]. Since depressive and anxiety disorders are prevalent among PD 
patients, their symptoms may lead to the aggravation of  PD symptoms as well as other 
co-morbid physical disorders. It is therefore possible that the reduced mortality associated 
with adherence to AD could be mediated, at least to some extent, via adherence to other 
life prolonging drugs (such as cardiovascular drugs for example) rather than AD. Another 
possible explanation that has been proposed is that depression is associated with negative 
health behavior and therefore AD usage may improve that behavior [29] . AD adherence 
is presumably associated with more mindful health behaviors (e.g. physical activity, 
healthy nutrition etc.) which may mediate the link between AD adherence and increased 
survival. If such, this explanation may also underlie the effect of AD adherence on 
survival in patients with PD demonstrated in our study. However, these hypotheses 
remain to be tested in future studies.  
Whilst the current study provides novel findings, it is important that the results are 
interpreted in light of a number of limitations. First, the analyses did not include data 
regarding the psychiatric diagnoses associated with the need for AD prescription, as 
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mental health diagnosis data in the database were incomplete. Second, data on causes of 
death were also not available, and thus we were unable to discriminate between death due 
to PD, suicide and other causes. Third, residual confounding by unmeasured variables, 
such as obesity, mobility limitations and physical inactivity, could have also influenced 
our findings. Fourth, due to insufficient power we did not stratify the results by AD 
compound. Future research should seek to explore if the association between AD 
adherence and mortality in PD differs between different AD medications. Fifth, we did 
not have information on cognitive impairment and dementia in our sample which may 
have influenced AD adherence and mortality. Future research may wish to consider the 
potential impact of cognitive impairment on the relationship between AD adherence and 
mortality in those with PD. Finally, we did not have a measure of PD disease symptom 
severity with our sample.  Future research should seek to investigate the impact of this on 
mortality outcomes.  
Despite the aforementioned caveats, our study has several key strengths. Our 
measure of adherence was shown to be reliable [19] and provides important clinical 
information on the rate of non-adherence. The large sample size (N=8,553) encompassed 
a nationwide sample of all PD patients who used AD in the CHS database without an age 
limitation, making it the largest study of its kind. Therefore our findings are generalizable 
to the general population. Moreover, the Israeli healthcare delivery system is similar to 
those in other Western countries and thus our findings are also generalizable to these 
settings. The four-year follow-up period of the present study is long enough to evaluate 
mortality as an outcome measure, while permitting a large person-time denominator and 
establishment of causal pathways. 
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In conclusion, the present four-year follow-up study is the first to demonstrate the 
inverse association between adherence to AD and all-cause mortality in a general 
population-based large cohort of patients with PD (N=8,553) . Even though the 
standardized effect size of AD may be lower than previously thought [30], the beneficial 
effect of adherence to AD may be particularly important in the high-risk population of 
patients with PD. We suggest that neurologists, psychiatrists and primary-care 
physicians, prioritize the diligent use and efforts to enhance their patients' adherence to 
AD when indicated, as it may be associated with increased life-expectancy.  
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Table 1: Total patients with Parkinson's disease population (N=8,553) characteristics and 
mortality rates across demographic and clinical variables. 
 
  Population  Mortality  
  N % N % 
Total  8,553  2,068 24.2 
Gender Males 3,957 46.3 1,105 27.9* 
Females 4,596 53.7 963 21 
Age at study entry 18-24 5 0.0 0 0.0 
25-44 324 3.8 6 1.9 
45-64 1,449 16.9 104 7.2 
65-74 1,743  20.4 269 15.4 
75-84 3,573 41.8 1,009 28.2 
>85 1,459 17.1 680 32.9 
Socio-economic status Low 2,742 32.1 637 23.2 
Moderate 3,659 42.9 879 24 
High 2,128 25 542 25.5 
CCI 0-2 5,198 60 913 17.8 
3-4 1,948 22.8 570 29.3* 
>5 1,470 17.2 585 39.8* 
 
*P<0.05 
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Table 2: Hazard ratios (HR) for mortality using Cox regression survival analysis by 
antidepressants adherence category among patients with Parkinson's disease 
 
Adherence 
category 
Crude Adjusted 1 Adjusted 2 
<0.2 1.24 (1.1-1.4) 1.41 (1.24-1.6) 1.43 (1.26-1.62) 
0.2-0.5 1.22 (1.07-1.38) 1.26 (1.1-1.43) 1.26 (1.1-1.44) 
0.5-0.8 0.96 (0.86-1.08) 1 (0.9-1.13) 1.02 (0.9-1.15) 
>0.8 (Ref.) 1 1 1 
 
Bold= p<0.05 
Adjusted 1: Gender and Age (HR males vs. females: 1.49 (1.36-1.62)) 
Adjusted 2: Gender, Age and Charlson’s Comorbidity Index 
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Highlights: 
• Depression is common in Parkinson's Disease (PD)  
• The beneficial effect of antidepressants may be particularly important in PD   
• Poor adherence to antidepressants is associated with a 26%-43% increased 
mortality 
• Promoting antidepressant drug adherence should be a top clinical priority in PD  
  
 
 
 
 
